Manchester, UK, 23 February 2010 - F2G Limited, the Manchester UK based antifungal drug discovery and development company, today announced the appointment of Dr Richard J. White as Chairman of the Company’s Board of Directors. Dr White has served as a non-executive director of F2G Ltd since April 2006.
F2G also announced the appointment of a new non-executive director, Dr Sten Verland of Sunstone Capital A/S.
“I congratulate Richard on his appointment as Chairman” said Shane M. Kelly, Chief Executive of F2G Ltd. “Richard has a wealth of experience in infectious disease drug discovery gained within Biotech and Pharma. He has been a tremendous asset to the Company during his time on the Board and I look forward to working with him towards the further development of F2G Ltd. The Board also welcomes Dr Sten Verland, whose proven expertise in building successful businesses will be a valuable addition to the team.”
Dr Richard J. White commented ”This an exciting time for F2G as our lead program progresses to clinical testing and I eagerly anticipate working closely with the other Board members”.
About F2G Ltd:
Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. The antifungal market is currently estimated at over 6 billion dollars annually and is growing steadily year on year. Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma.
The company has impressive internal capabilities, employing a core team of scientists with a unique understanding of the antifungal arena, supported by an experienced management team. F2G operates a flexible business model, building value through the development of a balanced portfolio of antifungal assets across multiple validated TPPs.
For more information visit www.f2g.com
